rct
    2014
    High Quality

    Silexan in generalized anxiety disorder: investigation of the efficacy and tolerability in a randomized, double-blind, placebo-controlled trial with paroxetine as active control

    Kasper S, Gastpar M, Muller WE

    Published in International Journal of Neuropsychopharmacology

    Key Findings

    Silexan 160 mg/day significantly reduced HAMA scores versus placebo; paroxetine did not separate significantly.

    Conclusions

    Non-inferior signal to an SSRI comparator in GAD.

    Limitations

    Underpowered active comparator arm.

    Supplements Studied

    Silexan 160 mg/day significantly reduced HAMA total score versus placebo in generalized anxiety disorder.

    Related Health Concerns

    Anxiety

    Study Details

    Year:2014
    Sample Size:539
    Duration:10 weeks
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.